Christine
06-19-2007, 05:20 AM
http://medicineworld.org/images/blogs/thumbs/2-2007/herceptin-injection-thumb.jpgUsing gene chips to profile tumors before therapy, scientists at Harvard and Yale Universities found markers that identified breast cancer subtypes resistant to Herceptin, the primary therapy for HER2-positive breast cancer. They say this advance could help further refine treatment for the 25 to 30 percent of patients with breast cancer with this class of tumor........
More... (http://medicineworld.org/cancer/lead/2-2007/gene-profiling-and-resistance-to-herceptin.html)
More... (http://medicineworld.org/cancer/lead/2-2007/gene-profiling-and-resistance-to-herceptin.html)